RxDoctor Payments Data

Mohinder Poonia, MD

Cardiovascular Disease · Fresno, CANPI 1245388412

Payments from drug & device makers

$2,562in general payments, 2019–2025

Across 144 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$571
  • Boehringer Ingelheim$399
  • Pfizer$327
  • GSK$300
  • Ironwood Pharmaceuticals, Inc$149
  • Merck$144
  • plus $673 from 15 others

What the payments were for

  • Food & beverage$2,554100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,562 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$419,253
Medicare patients
289
Services billed
4,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$69,762
JanuviaSitagliptin Phosphate49$63,248
EliquisApixaban38$52,613
LinzessLinaclotide26$27,982
FarxigaDapagliflozin Propanediol20$22,179
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog47$20,987
JardianceEmpagliflozin23$17,896
Metoprolol Succinate602$10,761
TradjentaLinagliptin11$10,410
Atorvastatin Calcium754$4,465
Gabapentin199$3,999
Omeprazole291$3,126
Albuterol Sulfate HfaAlbuterol Sulfate64$2,681
Ibuprofen364$2,633
Diclofenac Sodium27$2,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$39$69,76275 claims
MerckJanuvia$144$63,24849 claims
PfizerEliquis$327$52,61338 claims
Boehringer IngelheimJardiance, Tradjenta$399$28,30634 claims
AbbVieLinzess$30$27,98226 claims
AstraZenecaFarxiga$571$22,17920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →